What's Happening?
Venture Medical, LLC has issued a statement regarding the Centers for Medicare & Medicaid Services (CMS) Calendar Year 2026 Physician Fee Schedule (PFS) Final Rule. This new rule introduces a framework for Medicare reimbursement of skin substitutes, setting
a $127 PFS rate. John Schroeder, CEO of Venture Medical, expressed concern that this rate could severely compromise access to therapies and specialized wound care. The rule is seen as a defining moment for the wound care industry, aiming to foster a balanced, evidence-based market that rewards quality and clinical performance. Venture Medical, a leading distributor of advanced wound care solutions, has long advocated for clarity and consistency in coverage and reimbursement. The company plans to work with industry colleagues, CMS, policymakers, and key opinion leaders to improve reimbursement and access to skin substitutes.
Why It's Important?
The CMS 2026 Physician Fee Schedule Final Rule has significant implications for the wound care industry, particularly in terms of reimbursement and access to specialized therapies. The $127 PFS rate, coupled with restrictive product coverage, could limit patient access to necessary wound care treatments. This change may affect elderly and vulnerable patients who rely on these therapies for effective care. Venture Medical's proactive approach to navigating these updates highlights the industry's need to adapt to new reimbursement structures while maintaining high standards of patient care. The company's commitment to advocacy and innovation is crucial in ensuring that clinicians can continue to deliver outcomes-driven care despite financial and regulatory challenges.
What's Next?
Venture Medical plans to accelerate its efforts in collaboration with industry colleagues, CMS, policymakers, and key opinion leaders to address the challenges posed by the new reimbursement structure. The company aims to improve access to skin substitutes and alleviate threats to patient care. As the market transitions to standardized reimbursement, Venture Medical is focused on leading change by offering education, policy guidance, and product solutions that meet clinical and economic demands. The company's strategic initiatives are designed to help customers navigate the updates and sustain operational excellence in a changing landscape.
Beyond the Headlines
The CMS 2026 Physician Fee Schedule Final Rule reflects broader trends in healthcare reimbursement, emphasizing evidence-based practices and quality outcomes. This shift may encourage innovation and compliance within the wound care industry, potentially leading to improved patient care standards. However, the restrictive nature of the rule could also prompt discussions about the balance between cost control and patient access to necessary treatments. Venture Medical's response underscores the importance of industry collaboration and advocacy in shaping healthcare policies that prioritize patient needs.
